Bristol-Myers Squibb Company (BMY) $59.60
Bristol-Myers Squibb (BMY) currently trades near its 52-week high, yet a closer look reveals a complex technical setup that demands caution before committing capital.
52-wk High $62.89
π Investment Snapshot
- π° BMY trades at $59.60, a modest 17.23x TTM P/E, below the S&P 500 average.
- π Latest quarter revenue hit $12.50B, with EPS at $0.54, showing some volatility.
- π A strong 4.23% dividend yield and robust institutional ownership anchor investor interest.
- π― Analysts maintain a ‘Hold’ consensus with a $62.72 target, implying limited near-term upside.
BMY’s technical confluence score registers a strong 90/100, signaling robust underlying strength across multiple indicators. However, the stock’s RSI is not oversold, and the consensus price target offers less than 15% upside, preventing a ‘Buy’ call at current levels.
| π Entry Zone | $58.50 or below | π Stop-Loss | $57.50 |
| π Adjust If | A confirmed break above the 52-week high of $62.89 on above-average volume, or a deeper pullback towards the $57.00 range, would warrant a re-evaluation of the entry strategy. | ||
The Investment Case β Why Now?
Bristol-Myers Squibb finds itself at a pivotal juncture, having delivered a strong 13.0% return over the past three months, yet experiencing a 3.4% dip in the last month. This recent volatility, combined with the stock’s proximity to its 52-week high, creates a challenging environment for new entries. Investors must weigh the company’s attractive 4.23% dividend yield against concerns surrounding patent expirations and pipeline execution.
The primary risk to BMY’s investment thesis centers on its ability to successfully navigate upcoming patent cliffs for key revenue drivers like Eliquis and Opdivo. A failure to introduce new blockbuster drugs or execute strategic acquisitions could severely impact future revenue growth and profitability. The latest quarterly EPS of $0.54, significantly lower than previous quarters, underscores the pressure on the company’s earnings power.
π€ Given the strong technical signals but limited consensus upside, what specific catalyst would compel you to initiate a position in BMY above its current trading range?
π’ Company Overview
| Detail | Value |
|---|---|
| Company | Bristol-Myers Squibb Company |
| Ticker / Exchange | BMY / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | Giovanni Caforio |
| Founded / HQ | 1887 / New York, NY |
π Price Action & Technicals
Golden Cross
Inside VA
A sell-side sweep occurred at $60.19 on April 1, 2026, indicating potential resistance.
BMY’s price action shows a stock consolidating near its 52-week high, trading above both its SMA50 ($58.58) and SMA200 ($49.67), a bullish alignment. The MACD registers a golden cross, with its line above the signal, further confirms positive momentum. However, the RSI at 55.0 remains neutral, neither signaling overbought nor oversold conditions, suggesting a balanced sentiment.
The ADX at 23.2 with a +DI (27.6) above the -DI (24.0) confirms a developing bullish trend, albeit not yet a strong one. Price currently sits within the upper quartile of the Bollinger Bands, indicating recent upward pressure, but the recent sell-side sweep at $60.19 warns of potential overhead supply. Volume is running slightly above average at 1.07x, lending some credibility to recent moves.
The Anchored VWAP from Q4 2025 earnings at $53.64 sits significantly below the current price, acting as a strong support level. Similarly, the Volume Profile's Point of Control (POC) at $45.2 and Value Area (VA) extending up to $60.58 suggest that the current price is at the upper end of the most traded range, potentially facing resistance. Several unfilled bullish FVGs below the current price ($59.08-$59.31, $57.1-$58.04, $55.33-$55.85) present potential targets for a pullback.
BMY’s Technical Confluence Score of 90/100 is exceptionally strong, driven by favorable VWAP, Volume Profile, and Liquidity Sweep signals. This score underscores the technical strength, but the prevailing neutral RSI and proximity to the 52-week high suggest that the ideal entry point for a high-conviction long trade may lie slightly lower, aligning with these unfilled FVGs.
π€ Considering the strong technical confluence but the recent sell-side sweep, would you prioritize waiting for a pullback to an unfilled FVG or a decisive break above the 52-week high?
β Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| BMY | Bristol-Myers Squibb | 17.23x |
| PFE | Pfizer Inc. | 12.5x |
| MRK | Merck & Co., Inc. | 22.1x |
| JNJ | Johnson & Johnson | 19.8x |
| S&P 500 | Index Average | 21.0x |
π° Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $12.50B | $0.54 | |
| Q3 2025 | $12.22B | $1.08 | |
| Q2 2025 | $12.27B | $0.64 | |
| Q1 2025 | $11.20B | $1.20 |
Bristol-Myers Squibb generated $1.6 billion in free cash flow during the latest quarter, demonstrating its ability to fund operations and shareholder returns. This robust cash generation supports the company’s attractive 4.23% dividend yield, a key draw for income-focused investors.
BMY’s quarterly revenue has shown a steady, albeit modest, upward trend, with the latest quarter reaching $12.50 billion. EPS figures, however, exhibit greater volatility, with the most recent quarter’s $0.54 representing a notable dip from previous periods. This fluctuation highlights the ongoing challenges in managing R&D costs and patent expirations.
π Growth Drivers β What Moves the Stock
- Robust Dividend Yield π‘ Priced In β BMY’s 4.23% dividend yield remains a significant attraction for income-seeking investors, providing a steady return amidst market volatility.
- Pipeline Development π’ Upside Surprise β The company’s ongoing investment in R&D and a diverse pipeline of new drug candidates could offset revenue declines from patent expirations. Success in key therapeutic areas like oncology and immunology presents substantial upside.
- Strategic M&A Potential π’ Upside Surprise β BMY has a history of strategic acquisitions to bolster its portfolio. Future M&A activity could provide immediate revenue diversification and pipeline enhancements, mitigating patent cliff risks.
π¦ Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 198,727 |
| Blackrock Inc. | 176,825 |
| State Street Corporation | 97,980 |
| JPMORGAN CHASE & CO | 75,367 |
| Charles Schwab Investment Management, Inc. | 71,322 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| ELKINS DAVID VINCENT | Chief Financial Officer | Apr 1, 2026 | Sale | 30,000 |
| SHORT BARTIE WENDY | Officer | Mar 10, 2026 | Sale | 5,883 |
| PLENGE ROBERT M | Officer | Mar 10, 2026 | Sale | 17,501 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.5 |
β Key Risk Factors
Multi-billion dollar revenue impact
Delayed revenue growth
Margin compression
Increased financing costs
π€ How effectively can BMY’s current pipeline and M&A strategy truly mitigate the looming patent cliff risks, or is the market underestimating this challenge?
π― Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $75.0 | $62.72 | $40.0 | 25 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| HSBC | Hold | Mar 2026 | Maintains | |
| RBC Capital | Sector Perform | Feb 2026 | Initiates | |
| Piper Sandler | Overweight | Feb 2026 | Maintains | |
| Barclays | Overweight | Feb 2026 | Initiates | |
| Citigroup | Neutral | Feb 2026 | Maintains |
The analyst consensus leans towards ‘Hold,’ with a mean target of $62.72 suggesting only a modest 5.23% upside from current levels. This cautious stance reflects the mixed signals from BMY’s fundamentals and the competitive landscape.
π Bull vs Bear β Probability-Weighted Scenarios
π Bull Case
- Successful pipeline execution delivers new blockbuster drugs, significantly offsetting patent cliff impacts.
- Strategic M&A activity expands BMY’s market presence and diversifies its revenue base beyond current key products.
π Base Case
BMY continues to navigate patent expirations with moderate success, maintaining stable revenues through existing products and incremental pipeline contributions. The dividend remains attractive, but significant capital appreciation is limited by competitive pressures and R&D costs.
π» Bear Case
- Patent cliff impacts are more severe than anticipated, leading to steeper revenue declines and market share loss.
- Pipeline failures or regulatory setbacks prevent new product launches, exacerbating revenue pressures and eroding investor confidence.
π― Investor Action Plan β By Profile
Swing traders should avoid BMY at current levels due to its neutral RSI and proximity to overhead resistance. Look for a clear break above $60.20 on strong volume for a short-term long, or a dip to the $58.00 support for a bounce play, with a tight stop below $57.50.
Position investors should wait for a more favorable entry. Consider scaling into a position if BMY pulls back towards the $58.50 (SMA50) or the $57.10-$58.04 FVG zone. This offers a better risk-reward profile, aligning with the strong technical confluence at lower levels.
Long-term investors already holding BMY should hold their positions, supported by the attractive dividend yield and stable institutional ownership. New long-term entries should target pullbacks to strengthen the average cost basis, particularly if the stock approaches the Anchored VWAP at $53.64.
β Investor FAQ β People Also Ask
Q: What does BMY’s strong technical confluence score of 90/100 imply?
The 90/100 score indicates a highly aligned bullish technical setup across multiple indicators like VWAP, Volume Profile, Liquidity Sweeps, ADX, and FVG. This suggests underlying strength and potential for upward movement, but it does not override the need for an optimal entry point based on other criteria like RSI and target upside.
Q: Why is the verdict ‘WAIT’ despite the stock being near its 52-week high?
The ‘WAIT’ verdict stems from BMY’s neutral RSI (55.0), which is not oversold, and the limited upside to the consensus target (5.23%). While the stock shows strong technical signals, these factors suggest that a more attractive entry point, potentially on a pullback, would offer a better risk-reward ratio for new capital.
Q: How do insider transactions impact the outlook for BMY?
Recent insider transactions show multiple officers, including the CFO, engaged in sales during March and April 2026. While these could be for various personal reasons, a pattern of insider selling, especially near 52-week highs, can signal a lack of conviction in near-term upside from those closest to the company’s operations.
π Want to check the current price action yourself?
π Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investing in securities involves risks, and past performance is not indicative of future results. Always conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions.
All active positions and their real-time performance are tracked on our Investment Log.
#BMY #BristolMyersSquibb #HealthcareStocks #Pharma #StockAnalysis #DividendStocks #TechnicalAnalysis #WallStreet